Business
Inhibrx Reports First Quarter 2026 Financial Results
Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company") today reported financial results for the first quarter of 2026. The biopharmaceutical company has two programs in ongoing clinical trials.
About this update from Inhibrx Biosciences, Inc.
[{"type":"text","content":"SAN DIEGO, May 14, 2026 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company") today reported financial results for the first quarter of 2026. The biopharmaceutical company has two programs in ongoing clinical trials.","length":268,"tagName":"p"},{"type":"image","alt":"Inhibrx, Inc. logo (PRNewsfoto/Inhibrx, Inc.)","displaySize":"","headline":null,"caption":"Inhibrx, Inc. logo (PRNewsfoto/Inhibrx, Inc.)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":133,"url":"https://media.zenfs.com/en/prnewswire.com/fae7441a9e255131c816a20f83e3312b"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/xC7KVbaMcGEd2k2sIIuNYg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTIzNA--/https://media.zenfs.com/en/prnewswire.com/fae7441a9e255131c816a20f83e3312b","width":400,"height":133},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/w_XEdYC2SuVPL0XqB0caPg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTY0MDtoPTIxMw--/https://media.zenfs.com/en/prnewswire.com/fae7441a9e255131c816a20f83e3312b","width":400,"height":133}},"href":"https://mma.prnewswire.com/media/1063194/inhibrx_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"Recent Corporate Highlights and Upcoming Milestones","length":51,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"INBRX-106","length":9,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"In May 2026, we announced updated interim data from our randomized, first-line Phase 2 portion of the HexAgon study. The trial evaluated the safety and efficacy of INBRX-106, a hexavalent OX40 agonist, in combination with pembrolizumab (the combination arm) versus pembrolizumab monotherapy (the control arm) in first-line patients with treatment-naïve, PD-L1 positive (Combined Positive Score (CPS) ≥ 20) metastatic or unresectable recurrent Head and Neck Squamous Cell Carcinoma (HNSCC).","length":489,"tagName":"p"}]},{"val":[{"type":"text","content":"We plan to announce progression-free survival (PFS) data from the randomized Phase 2 trial in HNSCC in combination with pembrolizumab in the fourth quarter of 2026.","length":164,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":653,"olType":false}]},{"val":[{"type":"text","content":"ozekibart (INBRX-109)","length":21,"tagName":"p"},{"type":"list","items":[{"val...